Page last updated: 2024-10-22

amifostine anhydrous and Autoimmune Diseases

amifostine anhydrous has been researched along with Autoimmune Diseases in 2 studies

Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.

Autoimmune Diseases: Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.

Research Excerpts

ExcerptRelevanceReference
"This list comprises genetic diseases (xeroderma pigmentosum, glucose-6-phosphate dehydrogenase deficiency), autoimmune disorders (vitiligo, scleroderma, thyroiditis, perforating collagenosis), metabolic diseases (diabetes mellitus), cardiovascular diseases, neuro/psychiatric diseases and other medical conditions (hypoglycemia, hepatic cirrhosis, alcoholism)."2.43Amifostine administration during radiotherapy for cancer patients with genetic, autoimmune, metabolic and other diseases. ( Koukourakis, MI; Maltezos, E, 2006)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nayak, SK1
Panesar, PS1
Kumar, H1
Koukourakis, MI1
Maltezos, E1

Reviews

2 reviews available for amifostine anhydrous and Autoimmune Diseases

ArticleYear
p53-Induced apoptosis and inhibitors of p53.
    Current medicinal chemistry, 2009, Volume: 16, Issue:21

    Topics: Amifostine; Apoptosis; Autoimmune Diseases; Benzothiazoles; Humans; Li-Fraumeni Syndrome; Neurodegen

2009
Amifostine administration during radiotherapy for cancer patients with genetic, autoimmune, metabolic and other diseases.
    Anti-cancer drugs, 2006, Volume: 17, Issue:2

    Topics: Amifostine; Autoimmune Diseases; Combined Modality Therapy; Comorbidity; Genetic Diseases, Inborn; H

2006